Frontiers in cardiovascular medicine · 2026
Safety and efficacy of transcatheter embolization for pulmonary arteriovenous fistula: a 21-year retrospective study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lu Hong, Wang Jianming, Xiao Jiawang, Wang Zhongchao, Yao Hui, Li Benshen, Mi Yuan, Wang Qiguang
Аннотация
BACKGROUND: This study aimed to evaluate the safety and efficacy of transcatheter embolization (TCE) for pulmonary arteriovenous fistula (PAVF).
METHODS: From January 1, 2003 to December 31, 2024, 28 patients (13 male, 15 female) with 41 PAVFs underwent TCE. Changes in arterial oxygen saturation (SaO2), procedural success rate, reperfusion rate, and complications were evaluated.
RESULTS: The procedural success rate was 100%, with an immediate complete occlusion rate of 87.8%.Postoperative SaO2 was significantly higher than that before operation (92.0% vs. 84.1%, P < 0.001). The 41 PAVFs were divided into four groups (coil group [n = 6], MemoPart PDA occluder group [n = 22], ADO II group [n = 7], and AVP I group [n = 6]). The average diameter of the arteries was 3.17 ± 0.7 mm, 11.86 ± 3.31 mm, 5.98 ± 2.54 mm, and 8.72 ± 3.78 mm, respectively, showing a statistically significant difference between groups (P < 0.001). The average clinical follow-up time was 19.46 ± 26.04 months (range: 6-162 months). During the follow-up period, 2 patients (7.14%) developed fever and 1 patient (3.57%) developed pleural effusion. 1 case (14.29%) of PAVFs experienced reperfusion in the ADO II group, while reperfusion did not occur in the other three groups, and the difference was not statistically significant (P = 0.463).
CONCLUSION: The adaptable utilization of various occluders can enhance the success rate of achieving effective occlusion. TCE for PAVFs demonstrates high safety and efficacy, with excellent procedural success rates and sustained long-term outcomes.
METHODS: From January 1, 2003 to December 31, 2024, 28 patients (13 male, 15 female) with 41 PAVFs underwent TCE. Changes in arterial oxygen saturation (SaO2), procedural success rate, reperfusion rate, and complications were evaluated.
RESULTS: The procedural success rate was 100%, with an immediate complete occlusion rate of 87.8%.Postoperative SaO2 was significantly higher than that before operation (92.0% vs. 84.1%, P < 0.001). The 41 PAVFs were divided into four groups (coil group [n = 6], MemoPart PDA occluder group [n = 22], ADO II group [n = 7], and AVP I group [n = 6]). The average diameter of the arteries was 3.17 ± 0.7 mm, 11.86 ± 3.31 mm, 5.98 ± 2.54 mm, and 8.72 ± 3.78 mm, respectively, showing a statistically significant difference between groups (P < 0.001). The average clinical follow-up time was 19.46 ± 26.04 months (range: 6-162 months). During the follow-up period, 2 patients (7.14%) developed fever and 1 patient (3.57%) developed pleural effusion. 1 case (14.29%) of PAVFs experienced reperfusion in the ADO II group, while reperfusion did not occur in the other three groups, and the difference was not statistically significant (P = 0.463).
CONCLUSION: The adaptable utilization of various occluders can enhance the success rate of achieving effective occlusion. TCE for PAVFs demonstrates high safety and efficacy, with excellent procedural success rates and sustained long-term outcomes.